BeOne Medicines AG (ONC)

BeOne Medicines AG Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	35,585	27,811	17,435	9,766	7,472	2,017
Revenue Growth (YoY)	53.47%	59.51%	78.53%	30.69%	270.56%	-32.37%
Cost of Revenue	4,878	4,336	2,694	1,976	1,048	8,915
Gross Profit	30,708	23,475	14,741	7,790	6,425	-6,899
Selling, General & Admin	14,587	13,371	10,699	8,819	6,290	3,918
Research & Development	14,899	14,257	12,612	11,315	9,270	-
Amortization of Goodwill & Intangibles	-	-	-	-	4.76	5.52
Operating Expenses	29,385	27,628	23,311	20,134	15,565	3,924
Operating Income	1,323	-4,153	-8,570	-12,344	-9,140	-10,822
Interest Expense	-104.91	-107.56	-29.99	-131.77	-179.2	-117.33
Interest & Investment Income	286.42	456.72	554.78	493.74	79.1	130.37
Earnings From Equity Investments	-73.15	-75	-55.71	-25.4	-11.41	-3.21
Other Non Operating Income (Expenses)	-94.28	53.66	-279.99	-1,346	52.82	166.49
EBT Excluding Unusual Items	1,337	-3,825	-8,381	-13,353	-9,198	-10,646
Gain (Loss) on Sale of Investments	-52.65	-64.98	-48.74	-172.69	59.63	81.47
Gain (Loss) on Sale of Assets	-2.89	-	-	-	-	-
Other Unusual Items	-	-	2,573	-	-	-
Pretax Income	1,160	-3,890	-5,856	-13,526	-9,139	-10,565
Income Tax Expense	925.11	815.93	396.18	295.05	122.15	67.88
Earnings From Continuing Operations	234.93	-4,706	-6,252	-13,821	-9,261	-10,632
Minority Interest in Earnings	-	-	-	-	-	23.61
Net Income	234.93	-4,706	-6,252	-13,821	-9,261	-10,609
Net Income to Common	234.93	-4,706	-6,252	-13,821	-9,261	-10,609
Shares Outstanding (Basic)	108	105	104	103	93	83
Shares Outstanding (Diluted)	112	105	104	103	93	83
Shares Change (YoY)	7.37%	0.86%	1.22%	11.15%	11.16%	38.99%
EPS (Basic)	2.18	-44.70	-59.89	-134.01	-99.81	-127.09
EPS (Diluted)	2.10	-44.70	-59.89	-134.01	-99.81	-127.09
Free Cash Flow	3,488	-4,622	-12,192	-12,567	-9,921	-9,146
Free Cash Flow Per Share	31.11	-43.90	-116.79	-121.85	-106.92	-109.57
Gross Margin	86.29%	84.41%	84.55%	79.77%	85.98%	-
Operating Margin	3.72%	-14.93%	-49.15%	-126.40%	-122.31%	-536.69%
Profit Margin	0.66%	-16.92%	-35.86%	-141.52%	-123.93%	-526.10%
Free Cash Flow Margin	9.80%	-16.62%	-69.93%	-128.68%	-132.76%	-453.57%
EBITDA	2,377	-2,934	-7,975	-11,909	-8,851	-10,615
EBITDA Margin	6.68%	-10.55%	-45.74%	-121.94%	-118.44%	-
D&A For EBITDA	1,054	1,219	595.18	434.89	288.99	207.54
EBIT	1,323	-4,153	-8,570	-12,344	-9,140	-10,822
EBIT Margin	3.72%	-14.93%	-49.15%	-126.40%	-122.31%	-
Revenue as Reported	27,126	27,811	17,435	9,766	7,472	2,017

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q